Nephros Inc (NEPH) stock
Close on Nov 11, 2026Market cap $33.34MP/E 17.1Yield –
Nephros Inc grew revenue 20.4% to $21.58M over the twelve months to Sep 30, 2026. Operating income rose 26.6% to $1.83M, moving the operating margin from 8.1% to 8.5%. At the latest close the market valued the company at $33.34M, 17.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $33.34M
- P/E ratio
- 17.1
- Price to sales
- 1.54
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $21.58M
- Net income
- $1.91M
- EPS, diluted
- $0.18
- Diluted shares
- 11M
Trading
- Previous close
- $3.15
- Open
- $3.15
- Day's range
- $3.03 – $3.29
- Volume
- 32,737
- Average volume (20 days)
- 62,900
- Beta (5 years)
- 0.58
- 52-week range
- $2.66 – $6.42
- RSI (14 days)
- 40.8
- Volatility (1 year)
- 83.8%
- Relative volume
- 0.93×
- WACC
- 7.8%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NEPH | S&P 500 | Difference | NEPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.0% | -2.4% | −10.6 pts | ||
| 3 months | -28.1% | -1.2% | −27.0 pts | ||
| Year to date | -37.1% | +12.3% | −49.4 pts | ||
| 1 year | -29.1% | +12.4% | −41.5 pts | ||
| 3 years | +56.6% | +78.8% | −22.2 pts | +16.1% | +21.4% |
| 5 years | -59.9% | +75.2% | −135.0 pts | -16.7% | +11.9% |
| 10 years | +6.6% | +311.1% | −304.5 pts | +0.6% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nephros filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Update
- Results
- Update
About Nephros
Surgical & Medical Instruments & Apparatus
Nephros, Inc. develops and commercializes point-of-use water filtration products for medical and commercial applications. The company operates two medical filtration product lines: infection control microfilters and ultrafilters that remove bacteria, viruses, and endotoxins, and dialysis ultrafilters that purify water and bicarbonate concentrates used in hemodialysis treatments. Its commercial offerings feature carbon-based and carbon-free filters designed to eliminate taste, odor, lead, cysts, scale, and per- and polyfluoroalkyl substances. Nephros primarily serves hospitals, healthcare facilities, dialysis clinics, and foodservice and hospitality establishments, alongside laboratories, manufacturing plants, aviation environments, and government facilities.
Company profile, executives and historyNephros stock: common questions
What is Nephros's stock price?
NEPH closed at $3.07 on Nov 11, 2026, down 2.54% on the day. Over the past 52 weeks it traded between $2.66 and $6.42.
What is Nephros's market cap?
Nephros was worth $33.34M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NEPH's P/E ratio?
NEPH trades at 17.1 times earnings, based on diluted earnings per share of $0.18 over the twelve months to Sep 30, 2026.
How much revenue does Nephros make?
Nephros reported revenue of $21.58M for the twelve months to Sep 30, 2026, up 20.4% from a year earlier.
Does Nephros pay a dividend?
No. Nephros has not paid a cash dividend over the last twelve months.
How has NEPH stock performed over the past year?
Including dividends, NEPH returned -29.1% over the past year, against +12.4% for the S&P 500.
How many NEPH shares are sold short?
0M shares were sold short at the latest FINRA report, 0.12% of the float, or 1.0 days of average trading volume.
Who are Nephros's competitors?
Companies most similar to Nephros by business, industry and size include CTSO, BDMD, KRMD, UTMD, SNOA.
See a number that looks wrong?